BIOPSY-TO-ACTION

Science built around the biology of the tumor.

Tidewave turns a patient’s tumor biopsy into an active input for personalized treatment and ongoing biological insight.

THE BIOLOGICAL RATIONALE

Cancer is not one target.

Every tumor contains a complex and evolving landscape of antigens. Tidewave begins with material from a patient's own tumor, using it to educate dendritic cells and expose the immune system to a broader picture of the cancer - not just a single target. By combining whole-tumor antigen presentation with gene-enhanced immune activation, Tidewave aims to mobilize T-cells that can recognize multiple tumor antigens and support lasting immune surveillance.

THE POTENTIAL

Recognize more.

Recruit more.

Remember longer.

Tidewave is designed to activate a broader and more durable anti-tumor immune response by leveraging the full complexity of the tumor.

Broad tumor-antigen repertoire

Dendritic cells capture and present a wide range of tumor antigens, including neoantigens, from the patient's own tumor material.

CXCL9/10-enhanced immune recruitment

Engineered dendritic cells express CXCL9/10, which can help recruit and activate T-cells in the tumor microenvironment.

durability and immune memory

By activating multiple tumor-specific T-cells, Tidewave aims to support immune memory and long-term tumor control.

HOW TIDEWAVE'S Dendritic Cells THERAPY WORKS

From tumor to T-cells.

Tidewave's off-the-shelf dendritic cells capture tumor antigens and activate T-cells in vivo.

Ship to site

Cryopreserved, off-the-shelf product shipped and stored at point of care.

Capture tumor antigens

Dendritic cells capture and process a broad range of tumor antigens from the patient's tumor.

Present to T-cells

Dendritic cells present tumor antigens and activate T-cells, driving a broader anti-tumor response.

clinical strategy

First in lung cancer.
Designed to expand.

Tidewave's off-the-shelf dendritic cells capture tumor antigens and activate T-cells in vivo.

Pathologic response

Immune activation

ctDNA / MRD

Paired tumor biology

One patient. Multiple readouts.

By following tumor tissue, blood, and clinical outcomes together, we can see how the biology changes during treatment, not just whether a patient responds.

Our Development Plan

Science built around the biology of the tumor.

Cancer is not one target.

Recognize more.

Recruit more.